Status:
COMPLETED
Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff
Lead Sponsor:
Direction Centrale du Service de Santé des Armées
Conditions:
Sars-CoV2
Eligibility:
All Genders
18+ years
Brief Summary
COVID-19 is a pathology linked to the SARS-CoV-2 virus, a new virus of the coronaviridae family that emerged in China in December 2019 before rapidly becoming a pandemic according to the WHO on March ...
Eligibility Criteria
Inclusion
- 18 years of age or older;
- Military or civilian or contactual volunteer on duty at Percy hospital during the COVID-19 pandemic.
Exclusion
- Individuals who have displayed a severe form of early-onset COVID-19 who required intensive care management or hospitalization;
- Presence of factors modulating immunity with congenital or acquired immunosuppression:
- Medication: cancer chemotherapy, immunosuppressive drugs, biotherapy, corticosteroids
- Uncontrolled HIV infection or CD4 \<200/mm3 infection
- History of solid organ or hematopoietic stem cell transplants
Key Trial Info
Start Date :
June 4 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 15 2022
Estimated Enrollment :
499 Patients enrolled
Trial Details
Trial ID
NCT04408001
Start Date
June 4 2020
End Date
March 15 2022
Last Update
April 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital d'Instuction des Armées Percy
Clamart, France, 92140